Stock Ratings | CIBC lowered its target for CervoMed (CRVO) to $18, with a potential upside of 529.37%; Jefferies lowered its target for Apple (AAPL) to $263.66
Innate Pharma SA IPHA | 0.00 | |
Immix Biopharma, Inc. IMMX | 0.00 | |
Oric Pharmaceuticals, Inc. ORIC | 0.00 | |
Csquare, Inc. CSQR | 0.00 | |
CervoMed Inc. CRVO | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
HC Wainwright & Co.: Maintaining a "buy" rating on Innate Pharma ( Innate Pharma SA(IPHA.US) ), with a price target raised from $5 to $7.
HC Wainwright & Co.: Maintaining a "buy" rating on Immix Biopharma ( Immix Biopharma, Inc.(IMMX.US) ), while raising the price target from $20 to $25.
HC Wainwright & Co.: Maintaining a "buy" rating on ORIC Pharmaceuticals ( Oric Pharmaceuticals, Inc.(ORIC.US) ), with a price target raised from $25 to $27.
B of A Securities: Initial rating for Csquare ( Csquare, Inc.(CSQR.US) ) stock at "Buy", with a target price of $46.
CIBC: Maintaining a "buy" rating on CervoMed ( CervoMed Inc.(CRVO.US) ), while lowering the price target from $27 to $18.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Innate Pharma SA(IPHA.US) | to lift | $7.0 | $2.22 | 215.32% | HC Wainwright & Co. |
| Immix Biopharma, Inc.(IMMX.US) | to lift | $25.0 | $10.13 | 146.79% | HC Wainwright & Co. |
| Oric Pharmaceuticals, Inc.(ORIC.US) | to lift | $27.0 | $13.62 | 98.24% | HC Wainwright & Co. |
| MDA Space Ltd(MDA.US) | to lift | $60.0 | $33.41 | 79.59% | RBC Capital |
| BioMarin Pharmaceutical Inc.(BMRN.US) | to lift | $114.0 | $68.88 | 65.51% | Canaccord Genuity |
| Csquare, Inc.(CSQR.US) | Initial classification | $46.0 | $21.6 | 112.96% | B of A Securities |
| CervoMed Inc.(CRVO.US) | cut | $18.0 | $2.86 | 529.37% | CIBC |
| CytomX Therapeutics, Inc.(CTMX.US) | cut | $14.0 | $3.44 | 306.98% | Jefferies |
| Vanda Pharmaceuticals Inc.(VNDA.US) | cut | $20.0 | $5.02 | 298.41% | HC Wainwright & Co. |
| Bridger Aerospace Group Holdings, Inc.(BAER.US) | cut | $4.0 | $1.37 | 191.97% | Canaccord Genuity |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Roth Capital: Maintaining a "neutral" rating on DoorDash DoorDash(DASH.US) ) stock, while raising its price target from $200 to $220.
Canaccord Genuity: Maintaining a "Hold" rating on Lyft ( Lyft(LYFT.US) ), while raising the price target from $15 to $16.
Citigroup: Maintaining a "buy" rating on Cloudflare(NET.US) ) stock, while raising its price target from $265 to $400.
Evercore ISI Group: Maintaining its "Outperform Market" rating for Snowflake ( Snowflake(SNOW.US) ) stock, while raising its price target from $280 to $360.
Citigroup: Maintaining a "neutral" rating on Ziff Davis ( Ziff Davis, Inc.(ZD.US) ), while raising its price target from $48 to $59.
First Coverage
Morgan Stanley: Initial rating for Csquare ( Csquare, Inc.(CSQR.US) ) at "overweight", with a price target of $26.
Barclays: Standard Nuclear, Inc. Class A ( Standard Nuclear, Inc. Class A(STDN.US) ) initial rating at "overweight", with a price target of $17.
reduction
Jefferies: Downgraded Apple ( Apple Inc.(AAPL.US) ) to "Underperforming the Market," with a price target cut from $285.56 to $263.66.
JP Morgan: Downgraded Compass Minerals Intl ( Compass Minerals International, Inc.(CMP.US) ) to "underweight", with a price target cut from $30 to $27.
Canaccord Genuity: Maintaining a "buy" rating on Oklo stock ( Oklo Inc(OKLO.US) ), while lowering the price target from $125 to $100.
B. Riley Securities: Affirming a "buy" rating for Vanda Pharmaceuticals ( Vanda Pharmaceuticals Inc.(VNDA.US) ), with a reduced price target from $17 to $12.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.